Prognostic impact of CD133 expression in Endometrial Cancer Patients

G. Mancebo, J. M. Sole-Sedeno, O. Pino, E. Miralpeix, S. Mojal, L. Garrigos, B. Lloveras, P. Navarro, J. Gibert, M. Lorenzo, I. Aran, R. Carreras, F. Alameda

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


© 2017 The Author(s). To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+. The mean OS for CD133+ tumour patients was 161 months (95% CI, 154-168) as compared with 146 months (95% CI, 123-160) for those with CD133-tumors (p = 0.012). The mean PFS for CD133+ tumour was 159 months (95% CI, 149-168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour (p = 0.014). CD133+ tumours were less likely to have vascular invasion (p = 0.010) and more likely to be well differentiated (p = 0.034). C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731 (95% CI, 1.251-17.89; p = 0.022). CD133+ tumor status correlates with favorable prognosis of EEC. Our findings are in agreement with studies addressing brain and colorectal tumours.
Original languageEnglish
Article number7687
JournalScientific Reports
Issue number1
Publication statusPublished - 1 Dec 2017


Dive into the research topics of 'Prognostic impact of CD133 expression in Endometrial Cancer Patients'. Together they form a unique fingerprint.

Cite this